Navigation Links
Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
Date:5/18/2009

SAN FRANCISCO, May 18 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.

"A significant number of pediatric ADHD patients present with behaviors such as anger, resentfulness, defiance, and arguing with adults. It can be complicated for physicians and caregivers to find the right medication to control symptoms for children with ADHD exhibiting these behaviors," said Daniel Connor, MD, professor and division chief of child and adolescent psychiatry at the University of Connecticut Medical School. "When considered with the primary efficacy results of the current study, these data provide additional support for the clinical efficacy of INTUNIV for treating ADHD in this patient population."

On January 26, 2009, Shire filed a resubmission to the US Food and Drug Administration (FDA) of the New Drug Application to support approval for the treatment of ADHD in children and adolescents. Once available, INTUNIV will be the first selective alpha-2A receptor agonist approved for the treatment of ADHD.

INTUNIV Demonstrated Significant Efficacy in Secondary Endpoints

In this randomized, placebo-controlled, flexible-dose study, INTUNIV demonstrated significant ADHD symptom improvement in patients with oppositional symptoms as measured by the
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
2. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
3. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
6. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
7. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
10. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
11. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... ® Complete Knee System. ... th year since Zimmer first introduced the NexGen knee ... date, more than five million implantations of the NexGen knee ... the NexGen knee demonstrates the importance of design innovation and ...
(Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... WASHINGTON, Sept. 1, 2011 Lung Cancer ... approval of Xalkori (crizotinib) with non-small cell lung cancer ... based on data from two clinical trials, both of ... Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic ...
... Sept. 1, 2011 Roche Diabetes Care, makers of ... is proud to host its second annual Infusion Site ... highlight the importance of proper infusion site management for ... 1 diabetes who use an insulin pump. ...
Cached Medicine Technology:New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population 2Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4 2Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4 3
(Date:3/29/2015)... North American Seminars receives Texas Board ... Education Courses . , Utilizing Pilates to ... TPTA, approval # 56399TX      , The Interactive ... complex - 10.5 hours - Texas Board of Physical ... Treatment of the SI Joint - 10 hours - ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... game with knights, nature, and peasants. , The ... to Eurogamer. The popularity of these games grew over ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New York ... commemorated its three-year anniversary of being the only 24/7 ... 24-hour urgent care, Emergency Medical Care offers its clients ... Emergency Medical Care’s Urgent Care NYC services ... injuries, ear infections, fevers, insect bites, burns, animal bites, ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 One ... re-injury, according to research presented today at the American ... Day. The study examined the long term success of ... , “We examined survey data from 242 patients who ... author Justin P. Roe, MBBS, FRACS, from North Sydney ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., ... posters. The Who and the Doors played together at the ... According to Hawley, “The Who toured the United States heavily ... campuses. Perhaps the most famous Who poster was a poster ... Doors on August 2, 1968 at the Singer Bowl in ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2
... individuals, who constitute a rapidly growing population in the ... care utilization and cost. Yet more than ... age or age-related conditions, according to a new study ... the University of Michigan. "These findings are ...
... an inexpensive, FDA-approved hypertension medication may improve the ... In a report in the early edition of ... , Massachusetts General Hospital (MGH) investigators describe experiments ... the network of collagen fibers that characterizes most ...
... available in French . Montreal, February 2, ... (LGB) are at far higher risk for severe mental health ... suggests that the stress of being rejected or victimized because ... and bisexuals. Recently published as a doctoral thesis ...
... German . Lung tumors are the number one ... is lung cancer. Each year, there are 50,000 new cases of ... detected, the greater the chance of healing the patient. But early ... chronic inflammatory reactions. To get a more complete diagnosis, the patient ...
... thought to be active in killing cells also promotes cellular ... of RIP1 is actually necessary for survival of septic injury, ... potential for developing new treatments for sepsis PROVIDENCE, ... protein that plays a dual role in the liver during ...
... Children who grow up in poverty have health problems as ... live in communities with more social cohesiveness and control get ... be obese as adolescents. The new study, published in ... Psychological Science, is part of a long-term examination of children ...
Cached Medicine News:Health News:Older adults often excluded from clinical trials 2Health News:Generic drug may improve the effectiveness of cancer nanotherapies 2Health News:Physiological impacts of homophobia 2Health News:Physiological impacts of homophobia 3Health News:Early detection of lung cancer 2Health News:The 'death switch' in sepsis also promotes survival 2Health News:Having a strong community protects adolescents from risky health behaviors 2
Lorgnette pinhole occluder...
9 inch double ended with one end black and the other end with 49 holes...
6 inch hand held occlcuder with 49 holes...
Double Ended Occluders...
Medicine Products: